Regencell Bioscience Files Prospectus Supplement

TL;DR

Regencell Bioscience just filed a prospectus supplement for a new securities offering. Details TBD.

AI Summary

Regencell Bioscience Holdings Ltd. filed a prospectus supplement (424B5) on March 30, 2026, related to its registration statement (File No. 333-294722). The filing concerns the offering of securities, with specific details on the number of shares and price per share to be determined at the time of the offering.

Why It Matters

This filing indicates Regencell Bioscience is preparing to offer new securities, which could impact its stock price and capital structure.

Risk Assessment

Risk Level: medium — Prospectus supplements often precede new stock offerings, which can dilute existing shareholders or signal a need for capital, carrying inherent market risks.

Key Numbers

• 424B5 — Form Type (Indicates a prospectus supplement filing)
• 333-294722 — Registration File Number (Associated with the offering)

Key Players & Entities

• Regencell Bioscience Holdings Ltd (company) — Filer of the prospectus supplement
• 0001829667 (company) — CIK number for Regencell Bioscience Holdings Ltd
• 333-294722 (dollar_amount) — File number for the registration statement
• March 30, 2026 (date) — Filing date of the prospectus supplement

FAQ

Key Financial Figures

• $500,000,000 — ELL BIOSCIENCE HOLDINGS LIMITED Up to $500,000,000 of Ordinary Shares We have entered int
• $0.00001 — sale of our ordinary shares, par value $0.00001 per share, or Ordinary Shares, offered
• $500 m — ng an aggregate offering price of up to $500 million, from time to time through Unives
• $25.67 — Shares on the Nasdaq Capital Market was $25.67 per Ordinary Shares. Sales of our Ordi
• $0 — ross proceeds for cumulative sales from $0 up to $100,000,000; 2.0% for cumulative
• $100,000,000 — eeds for cumulative sales from $0 up to $100,000,000; 2.0% for cumulative sales in excess of
• $300,000,000 — e sales in excess of $100,000,000 up to $300,000,000; and 1.75% for cumulative sales in exce
• $ — uo;CEO”) and director; “US$,” “$” or “US do

Filing Documents

• ea0282909-424b5_regencell.htm (424B5) — 561KB
• ea028290901ex-fee.htm (EX-FILING FEES) — 13KB
• ea028290901_img1.jpg (GRAPHIC) — 8KB
• ea028290901_img2.jpg (GRAPHIC) — 8KB
• 0001213900-26-035916.txt ( ) — 714KB
• ea028290901ex-fee_htm.xml (XML) — 4KB

FORWARD-LOOKING STATEMENTS

FORWARD-LOOKING STATEMENTS S-iv PROSPECTUS SUPPLEMENT SUMMARY S-1 THE OFFERING S-11

USE OF PROCEEDS

USE OF PROCEEDS S-14 DIVIDEND POLICY S-15 CAPITALIZATION S-16

DESCRIPTION OF SECURITIES WE ARE OFFERING

DESCRIPTION OF SECURITIES WE ARE OFFERING S-18 TAXATION S-19 PLAN OF DISTRIBUTION S-25 EXPENSES OF THE Offering S-27 LEGAL MATTERS S-28 EXPERTS S-29 WHERE YOU CAN FIND MORE INFORMATION ABOUT US S-30 INCORPORATION OF DOCUMENTS BY REFERENCE S-31 PROSPECTUS ABOUT THIS PROSPECTUS ii

FORWARD-LOOKING STATEMENTS

FORWARD-LOOKING STATEMENTS iii OUR COMPANY 1

USE OF PROCEEDS

USE OF PROCEEDS 3 DESCRIPTION OF SHARE CAPITAL 4 ENFORCEABILITY OF CIVIL LIABILITIES 21 TAXATION 22 SELLING SHAREHOLDERS 23 PLAN OF DISTRIBUTION 24 LEGAL MATTERS 26 EXPERTS 27 WHERE YOU CAN FIND MORE INFORMATION ABOUT US 28 INCORPORATION OF DOCUMENTS BY REFERENCE 29 You should rely only on the information contained or incorporated by reference into this prospectus supplement, the accompanying prospectus, any free writing prospectus or any other offering materials we filed by us with the SEC. We have not, and the Sales Agent has not, authorized any other person to provide you with different information. If anyone provides you with different or inconsistent information, you should not rely on it. The information contained in, or incorporated by reference into, this prospectus supplement and the accompanying prospectus or any free writing prospectus is current only as of their respective dates. Our business, financial condition, results of operations and prospects may have changed since those dates. This prospectus supplement and the accompanying prospectus are an offer to sell only the securities offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. We are not, and the Sales Agent is not, making an offer to sell our Ordinary Shares in any jurisdiction where the offer or sale is not permitted. S-i ABOUT THIS PROSPECTUS SUPPLEMENT This prospectus supplement and the accompanying prospectus are part of a registration statement that we filed with the SEC using a “shelf” registration process. Under the shelf registration process, we may offer our Ordinary Shares described in the accompanying prospectus from time to time in one or more offerings, subject in certain cases to the receipt of regulatory approval. This document consists of two parts. The first part is this prospectus supplement, which describes the specific terms of this offering and adds to, and updates information contain

View Full Filing

View this 424B5 filing on SEC EDGAR